Novoheart Holdings Inc.reports financial results for the three months ended December 31, 2019. Amounts, unless specified otherwise, are expressed in Canadian dollars and are in accordance with International Financial Reporting Standards (IFRS).

Novoheart is pleased to announce that it has been named a 2020 Venture 50 Company, ranked among the TSX Venture Exchange’s top 50 best performing companies

Novoheart is pleased to announce the completion of a research and development contract sponsored by a top 10 global pharma. The contract deliverables will see Novoheart further expand its current testing capabilities of the MyHeart^TM Platform by designing and developing a new versatile High-Throughput microplate which will allow the screening of hundreds of drugs using engineered human ventricular Cardiac Tissue Strips (hvCTS).

Novoheart has been awarded a further grant from the Innovation and Technology Commission (ITC) of Hong Kong SAR Government. Combined with a cash rebate scheme and funding for hiring R&D talent, the Company is expected to receive a total of over HK$10 million ($1.67 million CAD) in grant awards from the ITC over the next 2 years.